<DOC>
	<DOC>NCT00944697</DOC>
	<brief_summary>To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.</brief_summary>
	<brief_title>A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy</brief_title>
	<detailed_description>Study OXN2502 is a pilot, exploratory, randomised, placebo-controlled, double-blind, single-dummy, parallel group study to assess efficacy and safety of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone in opioid-naïve subjects treated with pregabalin suffering from moderate to severe pain due to diabetic polyneuropathy.</detailed_description>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Inclusion criteria: Moderate to severe pain due diabetic polyneuropathy Opioidnaive subjects Exclusion criteria: Females who are pregnant or lactating Subjects with evidence of significant structural abnormalities of the gastrointestinal tract Subjects with evidence of impaired liver/kidney function upon entry into the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>